This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 25, 2013 /PRNewswire/
-- By all industry accounts, interest in remote patient monitoring is expected to remain strong in the coming years, as hospital readmission penalties in
the United States take effect in 2013, and as mHealth technologies become more pervasive in the care delivery system, according to a report from
Berg analysts estimate that 2.8 million people are currently monitored for a variety of conditions outside the clinical setting. This number is expected to continue its upward trajectory, with cardiac rhythm management, sleep therapy and telehealth becoming the most significant categories for remote monitoring devices by 2017.
Preventice, Inc., a leading developer of mHealth solutions, including the
BodyGuardian Remote Patient Monitoring System (BodyGuardian RMS) is poised to capitalize on this opportunity through its unique approach to strategic partnerships and its proprietary technology platform. Meanwhile, clinical trials are underway in
the United States and
Europe to quantify the impact of the BodyGuardian RMS on clinical care delivery.
In good company: Strategic partnerships According to
Jon Otterstatter, co-founder, president and CEO of Preventice, the company has established an enviable ecosystem of partners that have allowed it to build a remote monitoring platform that is secure, reliable and scalable.
"From day one, we have made it a priority to affiliate the Preventice brand with leaders in health care, wireless devices, sensor technology, and production processes," said Otterstatter. "As a result, we have built a remote monitoring platform that meets the most stringent privacy and security standards, that is reliable in a variety of clinical and non-clinical settings and that exceeds the usability expectations of today's sophisticated consumers."